The company’s fourth-quarter net sales reached $321.2 million, a 1% increase compared to the same period last year. While GAAP earnings per share rose to $0.35 from a loss of $0.11 in the previous year's quarter, adjusted earnings per share saw a slight dip to $0.52 from $0.53. For the full fiscal year, GAAP earnings reached $1.16 per share, a significant turnaround from the $0.46 reported in 2025.
In section Releases
Bio-Techne Reports Stable Fiscal Year Revenue Amid Pending Acquisition
Bio-Techne Corporation reported flat full-year revenue of $1.2 billion for fiscal 2026, even as it prepares for an $11.3 billion acquisition by Merck KGaA. The Minneapolis-based life sciences firm saw fourth-quarter organic revenue rise 3%, signaling steady demand for its research reagents and diagnostic platforms during the transition period.
Operational performance was supported by profitability initiatives and the divestiture of Exosome Diagnostics, which helped offset headwinds in product mix and volume. The Protein Sciences segment, a primary supplier of specialized proteins and antibodies, recorded $874.6 million in full-year sales, while the Diagnostics and Spatial Biology segment generated $336.4 million. As the company moves toward closing the deal with Darmstadt-based Merck KGaA for $73 per share, management has discontinued its practice of holding quarterly investor conference calls.
Comments (0)
No comments yet. Be the first!